New Vitalis Pharmacy (New Vitalis Pharmacy, LLC), Louisville, KY
Is New Vitalis Pharmacy (New Vitalis Pharmacy, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does New Vitalis Pharmacy (New Vitalis Pharmacy, LLC) hold a Kentucky pharmacy license?
State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts. The Colorado State Board of Pharmacy also lists nonresident license OSP 7921 for New Vitalis Pharmacy, Louisville, KY, status Active, as of Nov 15, 2026.
Has New Vitalis Pharmacy (New Vitalis Pharmacy, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (May 18, 2022) for New Vitalis Pharmacy (New Vitalis Pharmacy, LLC). State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- New Vitalis Pharmacy, LLC; New Vitalis Pharmacy
- Location
- Louisville, KY
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jul 5, 2023
- FDA Data Dashboard inspections
- 3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 21 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as New Vitalis Pharmacy, LLC, (dba New Vitalis Pharmacy), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jul 5, 2023 | Form 483 | 483 Issued 7/5/2023 | FDA copy (archived) |
| May 18, 2022 | Warning letter | Warning Letter (05/18/2022) | FDA copy (archived) |
| Aug 27, 2021 | Form 483 | 483 Issued 08/27/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists New Vitalis Pharmacy LLC, Louisville, KY (FEI number 3014391500), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 5, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014391500 | 1211023 |
| Aug 27, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014391500 | 1149996 |
| Sep 7, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014391500 | 1065457 |
Form 483s FDA has published for this site
- Jul 5, 2023: Form 483 to New Vitalis Pharmacy LLC, published Nov 1, 2023. fda.gov
- Aug 27, 2021: Form 483 to New Vitalis Pharmacy LLC, published Mar 9, 2022. fda.gov
- Sep 7, 2018: Form 483 to New Vitalis Pharmacy LLC, published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 21 numbered observations in all, across 3 inspections ending Sep 7, 2018 to Jul 5, 2023. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jun 12, 2023 to Jul 5, 2023: 11 observations
- Firm on the cover
- New Vitalis Pharmacy LLC dba New Vitalis Pharmacy, 4139 Cadillac Ct Ste 201, Louisville, KY 40213-1578
- FEI number
- 3014391500
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drugs
- FDA district office on the cover
- 550 Main Street Cincinnati, OH 45202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Failure to conduct post-use filter-integrity testing on filters used to sterilize drug products.
Specifically, your firm did not conduct post-use <Redacted B4> testing of the <Redacted B4> used in the production of the sterile finished drug products. For examples:
a. The <Redacted B4> used to aseptically fill <Redacted B4> vials of Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot AL-0511202:1 <Redacted B4>, on 06/14/2023 was discarded in the trash without conducting the post-use <Redacted B4> testing by your filling pharmacist.
b. Post use <Redacted B4> testing were not performed for the following drug product lot as well:
i. Testosterone Cypionate 180mg/mL/Testosterone Propionate 20mg/mL, lot AL-0314202}: <Redacted B4>, Exp. Date 05/09/2023. This lot was used to fill approximately <Redacted B4> prescriptions that were dispensed to patients.
ii. Testosterone Cypionate 180mg/mL/Testosterone Propionate 20mg/mL, AL-0426202 <Redacted B4> Exp. Date 06/25/2023. Approximately <Redacted B4> prescriptions filled and dispensed to patients between 04/17/2023 - 05/30/2023.
iii. ...
Observation 2
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
a. Your media fill program is deficient in that your media fills are not representative of batch sizes and container types. Your media fills are performed in batch sizes of <Redacted B4> vials however your firm routinely prepares <Redacted B4> batches into 2mL and 5 mL vials of Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL. In addition, your firm perform sterile to sterile production of sterile eye drop filled in a I0mL plastic dropper which requires some manipulations to add the caps while assembling the sterile dropper after aseptic filling of the droppers. This process has not been simulated in your media fill.
b. Media fills do not capture the worst-case processing conditions such as the number of aseptic manipulations in the hood. For example, bulk drug product is routinely, <Redacted B4> in the <Redacted B4> Hood using <Redacted B4> into the <Redacted B4> bottle part of the <Redacted B4> unit and stored inside the ISO 5 BSC hood pending contract testing lab results. ...
Observation 3
Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.
Specifically, on 06/14/2023, I observed your sterile operator <Redacted B4> blocking first air by placing supplies to include a tray of <Redacted B4> vials, empty carton, bottle of bulk drug product and the Repeated <Redacted B4> Pump with its connecting power cord in front of the HEPA filter in the ISO 5 <Redacted B4> LFH, while aseptically <Redacted B4> and filling sterile drug product vials of Testosterone Cypionate 180mg/mL/Testosterone Propionate 20mg/mL lot AL0511202}. <Redacted B4> between these supplies and the operator.
Vials used during the aseptic operations on 06/15/2023 were selected from the last row of the vial box in the ISO 5 <Redacted B4> LFH closest to the operator and filled behind the staged materials in the ISO LFH blocking First Pass air.
Observation 4
Use of a sporicidal agent in the facility's ISO 5 areas and classified areas was lacking.
Specifically, sporicidal agents were not used in your facility's ISO 5 classified aseptic processing area. Your firm's Pharmacist stated that he cleans and disinfects the ISO 5 BSC's and ISO 5 LFH with only <Redacted B4> Sterile pre-saturated wipes which were <Redacted B4>. The <Redacted B4> Sterile pre-saturated wipes consists of <Redacted B4> observes health on 06/14/2023 and 06/15/2023 before and after the aseptic filling of Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot AL05112023 <Redacted B4>. The ISO 5 LFH hood located in the non-hazardous IV cleanroom was only wiped with Sterile <Redacted B4> wipes that were , also sprayed with sterile <Redacted B4>. These hoods have been used in the aseptic filling of approximately <Redacted B4> sterile drug products, including Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL, Vancomycin and Papaverine/Phentolamine/Alprostadil (Tri-Mix) between May 19th 2023 and June 13th 2023.
Observation 5
Use of non-sterile cleaning wipes in the ISO 5 area.
Specifically, on 06/14/2023 and 06/15/2023, before and during filling of bulk Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot AL05112023 <Redacted B4> respectively, your pharmacist transferred the non-sterile wipe with the lot number of the drug product inscribed on it from BSC ISO 5 in the HD ISO 7 cleanroom to the non-HD ISO 7 cleanroom and then into the ISO 5 LFH for filling into the final drug product vials that will be distribute for patient use. Per your pharmacist this drug product bulk was prepared on 05/11/2023 and had been placed on this same non-sterile wipe since then.
Observation 6
Smoke studies were inadequately performed under dynamic conditions.
Specifically, you presented a report for smoke studies conducted by your third party <Redacted B4> on 1/26/2023. The smoke study reported for ISO 5 LFH located in the ISO 7 Non-Hazardous IV buffer room does not appear to have been conducted under dynamic conditions. Your pharmacist stated that he was not involved in the <Redacted B4> hood smoke study but only demonstrated dynamic manipulation of the <Redacted B4> hood which is located in the ISO 7 Hazardous chemical buffer room. This ISO 5 hood in the Non-Hazardous IV buffer room has been used in the aseptic filling of approximately <Redacted B4> prescliptions of your sterile products from March to May 2023, to include the following but not limited products: Vancomycin 5% eye drop and Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL
Observation 7
Use of a disinfectant in a manner insufficient to achieve adequate levels of disinfection.
Specifically, the disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate level of disinfection. You are not waiting the required <Redacted B4> dwell time for the disinfectants used to sanitize your ISO 5 hoods where sterile products ai·e compounded and ISO 7 buffer rooms. Your pharmacist stated that the disinfectants direction specifies waiting <Redacted B4> prior to wiping down.
Observation 8
Personnel infrequently sanitized gloves to prevent contamination.
Specifically, on 06/15/23, I observed operator <Redacted B4> use his gloved hands to clean the bulk drug product spills on the <Redacted B4> area which is <Redacted B4> approximately three times using a previously used <Redacted B4> in the ISO 5 LFH. He immediately continued the aseptic filling of vials with Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot 0511202 <Redacted B4> without sanitizing his gloves.
Observation 9
HEP A filters are not sealed around the perimeter.
Specifically, the HEPA filters in the ISO 7 non-hazardous room were not properly sealed. The perimeter of the HEPA filter did not overlap to the ceiling. The HEPA filters are not adequately sealed to the ceiling and had gaps." This is a repeat observation.
The ISO 5 Laminar Air Flow Hood (LFH) used in the aseptic filling of Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot AL0511202. <Redacted B4> vials on 06/14/2023 and 06/15/2023 is situated in this room.
Observation 10
The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.
Specifically, all material flows directly from an unclassified area into a negative pressure ISO 7 HD cleanroom in which sterile production occurs vial <Redacted B4>. Additionally, material for the non-HD production is also brought in through this <Redacted B4>.
a. On 06/14/2023 and 06/15/2023 I observed the operator pass the sterile packaged vials of Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL lot AL05112023 <Redacted B4> through to the unclassified area Non-Sterile Dry Lab through an unclassified material <Redacted B4> into the classified ISO 7 Hazardous Chemical Buffer cleanroom where compounding of aseptically manipulated drug products is conducted.
b. Additionally, microbial growth of 1 CFU/25cm 2 was recovered from this <Redacted B4> in the last certification from January 26, 2023, Test Report: 230126-1000. Microbial identification was Cladosporium species which is a common fungus.
c. ...
Observation 11
Use of processing aides not intended for pharmaceutical use in sterile drug production.
Specifically, your pharmacist stated that <Redacted B4> unit is used in the initial <Redacted B4> of Bulk Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/mL drug product. which is part of the production flow for the drug product. I observed this operation on 06/13/2022 during the bulk <Redacted B4> of Bulk Testosterone Cypionate 180mg/mL Testosterone Propionate 20mg/m lot 061220231 <Redacted B4> using the non-pharmaceutical grade <Redacted B4> unit. In addition the certificate of Quality (COQ) stated that "This product is not intended for use in direct patient cai·e or diagnostic procedures".
Inspection Aug 23, 2021 to Aug 27, 2021: 7 observations
- Firm on the cover
- New Vitalis Pharmacy LLC dba New Vitalis Pharmacy, 4139 Cadillac Ct Ste 201, Louisville, KY 40213-1578
- FEI number
- 3014391500
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drugs
- FDA district office on the cover
- 6751 Steger Drive Cincinnati, OH 45237-3097
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Vermin was observed in an area immediately adjacent to your production area.
Specifically, on 08/24/2021, the Pharmacist-in-Charge stated the ISO 7 cleanroom was clean and ready for compounding use. While you were producing Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials, lot 08242021@901, two apparent dead flies were noted on the floor; one behind the ISO 5 hood and one near the trash can which is positioned directly beside the right side of the ISO 5 hood.
Observation 2
Non-microbial contamination was observed in your production area.
Specifically, on 08/24/2021, the Pharmacist-in-Charge stated the ISO 7 cleanroom was clean and ready for compounding use. While you were producing Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials, lot 08242021@901, the following were observed in the ISO 7 cleanroom:
• Black specs of apparent debris were observed on the floor throughout the ISO 7 cleanroom .
• <Redacted B4> tape reading "RESTRICTED AREA" was tapped on the floor by the door and was observed to bepeeling and bubbling up with apparent build-up of black residue on the peeling tape.
• The ceiling has apparent black residue built-up around <Redacted B4> HEPA filters.
Observation 3
Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.
Specifically, in the vertical airflow ISO 5 hood you were observed hand-stoppering Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials, lot 08242021@901, after the vials were filled, while your hand and forearm were over the exposed sterile injectable product vials.
Observation 4
HEPA filters were not sealed around each perimeter to the support frame.
Specifically, HEPA filters are not sealed in the ISO 7 cleanroom identified as the room where sterile compounding occurs. One of the HEPA filters was observed having a corner hanging loose from the ceiling. Additionally, the entire <Redacted B4> ceiling in the ISO 7 cleanroom is caulked along all the seams and the caulk appears to be jagged and rough with pieces that could potentially fall off. There is also a <Redacted B4> sprinkler head located directly above the ISO 5 hood where sterile compounding occurs.
n 6)1~)7
Observation 5
Personnel did not disinfect to prevent contamination.
Specifically, while you were producing Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials, lot 08242021@901, you did not disinfect your gloves when you re-entered the ISO 5 hood after collecting a vial rack and bag of stoppers. You also did not wipe down the bag of stoppers with your <Redacted B4> sterile wipes when t ransferring from a lesser air quality to a higher air quality prior to introduction in the ISO 5 hood.
Lastly, on 08/24/2021 while you were producing the sterile drug product Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials, lot 08242021@901 in your ISO 5 hood, we observed vials and stoppers being used that according to the Pharmacist-in-Charge had been stored uncovered in the ISO 5 hood since 08/19/2021.
Observation 6
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, your mask was not covering your nose while producing Testosterone Cypionate 180mg/Testosterone Propionate 20 mg/ml in 1 ml vials for lot 08242021@901, a sterile injectable drug product. Additionally, you attempted to fix the mask twice using your sterile gloved hand and did not sanitize your gloved hand while continuing compounding activities.
Observation 7
You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.
Specifically, you have inadequate cleaning for your non-dedicated <Redacted B4> Blender, which blends active pharmaceutical ingredients such as progesterone and melatonin. You are currently using non-pharmaceutical grade detergents to clean equipment used in pharmaceutical compounding.
Inspection Aug 27, 2018 to Sep 7, 2018: 3 observations
- Firm on the cover
- New Vitalis Pharmacy LLC dba New Vitalis Pharmacy, 4139 Cadillac Ct, Suite 201, Louisville, KY 40213-1578
- FEI number
- 3014391500
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drug Products
- FDA district office on the cover
- Cincinnati, OH 45237-3097
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess. Specifically,
Your firm produced finished Testosterone Cypionate 200MG/ML in Grapeseed Oil lots AL07192018@906 and AL-08072018@901 using apparent food-grade Grapeseed oil supplied by <Redacted B4> and labeled by the manufacturer as "Caution: Dietary Supplement." According to your firm's batch record,
Your firm produced <Redacted B4> finished vials of lot AL-07192018@906 using Grapeseed Oil, lot 1801260072. For example, the shipping record shows that a vial of lot AL-07192018@906 was delivered to <Redacted B4> in <Redacted B4> on 08122118.
Your firm produced <Redacted B4> finished vials of lot AL-08072018@901 using Grapeseed Oil, lot 1801260072. For example, the shipping record shows that a vial of lot AL-08072018@901 was delivered to <Redacted B4> Oil 08/29/18.
Observation 2
Visual inspection of finished drug products prior to distribution is not adequately performed. Specifically,
Your firm <Redacted B4> sterilized Testosterone Cypionate 200 MG/ML in Grapeseed Oil injectable lots AL-07192018@906 and AL-08072018@901 at <Redacted B4> for <Redacted B4> minutes, respectively on 07/24/18 and 08/07/18. Your firm stated that 100% visual checks are performed on each lot prior to labeling and dispensing or distribution to your patient. However, your firm does not utilize any black or white box or additional lighting source to examine for visible paiticulates, cloudiness, and/or discoloration in the finished vials.
For example: •
Your firm produced <Redacted B4> produced <Redacted B4> finished vials from lot AL-07192018@906. Your firm shipped a vial from this lot <Redacted B4> in <Redacted B4> on 08/22/18.
Your firm produced <Redacted B4> l finished vials from lot AL-08072018@901. Your firm shipped a vial from this lot to RX <Redacted B4> in <Redacted B4> on 08/29/18.
Observation 3
Non-sterile, low-shedding wipes are used to cleaned the ISO 5 hoods. Specifically,
On 08/27/18, I observed non-sterile wipes <Redacted B4> in the ISO 7 clean room. Your firm stated that these non-sterile wipes utilized during the routine cleaning of the ISO 5 hoods.
State board of pharmacy records
State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7921 | OSP | New Vitalis Pharmacy | Louisville, KY | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.